Crispr Therapeutics and MaxCyte announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow Crispr Therapeutics to deploy MaxCyte’s flow electroporation technology to develop Crispr/Cas9-based therapies in immuno-oncology. The expanded relationship builds on an existing agreement announced in March 2017 which allowed for the development of commercial therapeutics for hemoglobin-related diseases. Under the terms of the new license agreement, Crispr Therapeutics will obtain non-exclusive development and commercial-use rights to MaxCyte’s cell engineering platform to develop immuno-oncology cell therapies. MaxCyte will supply its technology to Crispr Therapeutics as part of the enabling technology license agreement and will receive milestone and sales-based payments in addition to other licensing fees.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.